Why Are Argenx Shares Trading Higher Today?
Portfolio Pulse from Vandana Singh
Argenx SE reported positive results from the ADHERE study evaluating Vyvgart Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The study met its primary endpoint with a 61% reduction in the risk of relapse versus placebo with up to 48 weeks of treatment. Argenx has an exclusive license agreement with Zai Lab Limited for developing and commercializing Vyvgart and Vyvgart Hytrulo in Greater China. Following the news, ARGX shares are up 27.10% and ZLAB stock is up 7.72% in the premarket session.
July 17, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argenx reported positive results from the ADHERE study, leading to a 27.10% increase in its share price.
The positive results from the ADHERE study evaluating Vyvgart Hytrulo in adults with CIDP have significantly boosted investor confidence in Argenx, leading to a sharp increase in its share price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Zai Lab, which has an exclusive license agreement with Argenx for developing and commercializing Vyvgart and Vyvgart Hytrulo in Greater China, saw its stock price increase by 7.72%.
Zai Lab's exclusive license agreement with Argenx for developing and commercializing Vyvgart and Vyvgart Hytrulo in Greater China has positively impacted its stock price following the positive results from the ADHERE study.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 70